bioMerieux : Q4 2023 sales and full-year earnings in line with the consensus. Guidance for 2024 contributive revenue below current estimates
>Q4 +3.1% l-f-l: - operating margin: 16.6% - Q4 sales came to € 1,006m (-2.2% and +3.1% l-f-l / Visible Alpha consensus: € 1,009m est. - FactSet consensus: € 1,005m est.), for € 3,674.7m over the full year (+2.4% and +6.6% l-f-l / Visible Alpha css: € 3,678m est. - FactSet css: € 3,674m est.), with an FX effect of -€ 141m ($, yuan, Argentine Peso), and underlying operating profit before GW came to € 610m, -8.2 % and +2% l-f-l (vs css: € 594m-635m est.) or an operatin...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.